Literature DB >> 33688039

The Negative Allosteric Modulator EU1794-4 Reduces Single-Channel Conductance and Ca2+ Permeability of GluN1/GluN2A N-Methyl-d-Aspartate Receptors.

Riley E Perszyk1, Zhaoshi Zheng1, Tue G Banke1, Jing Zhang1, Lingling Xie1, Miranda J McDaniel1, Brooke M Katzman1, Stephen C Pelly1, Hongjie Yuan1, Dennis C Liotta1, Stephen F Traynelis2.   

Abstract

NMDA receptors are ligand-gated ion channels that mediate a slow, Ca2+-permeable component of excitatory synaptic currents. These receptors are involved in several important brain functions, including learning and memory, and have also been implicated in neuropathological conditions and acute central nervous system injury, which has driven therapeutic interest in their modulation. The EU1794 series of positive and negative allosteric modulators of NMDA receptors has structural determinants of action near the preM1 helix that is involved in channel gating. Here, we describe the effects of the negative allosteric modulator EU1794-4 on GluN1/GluN2A channels studied in excised outside-out patches. Coapplication of EU1794-4 with a maximally effective concentration of glutamate and glycine increases the fraction of time the channel is open by nearly 1.5-fold, yet reduces single-channel conductance by increasing access of the channel to several subconductance levels, which has the net overall effect of reducing the macroscopic current. The lack of voltage-dependence of negative modulation suggests this is unrelated to a channel block mechanism. As seen with other NMDA receptor modulators that reduce channel conductance, EU1794-4 also reduces the Ca2+ permeability relative to monovalent cations of GluN1/GluN2A receptors. We conclude that EU1794-4 is a prototype for a new class of NMDA receptor negative allosteric modulators that reduce both the overall current that flows after receptor activation and the flux of Ca2+ ion relative to monovalent cations. SIGNIFICANCE STATEMENT: NMDA receptors are implicated in many neurological conditions but are challenging to target given their ubiquitous expression. Several newly identified properties of the negative allosteric modulator EU1794-4, including reducing Ca2+ flux through NMDA receptors and attenuating channel conductance, explain why this modulator reduces but does not eliminate NMDA receptor function. A modulator with these properties could have therapeutic advantages for indications in which attenuation of NMDA receptor function is beneficial, such as neurodegenerative disease and acute injury.
Copyright © 2021 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33688039      PMCID: PMC8058507          DOI: 10.1124/molpharm.120.000218

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  69 in total

1.  Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial.

Authors:  R L Sacco; J T DeRosa; E C Haley; B Levin; P Ordronneau; S J Phillips; T Rundek; R G Snipes; J L Thompson
Journal:  JAMA       Date:  2001-04-04       Impact factor: 56.272

2.  Context-dependent GluN2B-selective inhibitors of NMDA receptor function are neuroprotective with minimal side effects.

Authors:  Hongjie Yuan; Scott J Myers; Gordon Wells; Katherine L Nicholson; Sharon A Swanger; Polina Lyuboslavsky; Yesim A Tahirovic; David S Menaldino; Thota Ganesh; Lawrence J Wilson; Dennis C Liotta; James P Snyder; Stephen F Traynelis
Journal:  Neuron       Date:  2015-02-26       Impact factor: 17.173

Review 3.  The developmental stages of synaptic plasticity.

Authors:  Christian Lohmann; Helmut W Kessels
Journal:  J Physiol       Date:  2013-10-21       Impact factor: 5.182

Review 4.  Getting the most out of noise in the central nervous system.

Authors:  S F Traynelis; F Jaramillo
Journal:  Trends Neurosci       Date:  1998-04       Impact factor: 13.837

5.  Coupling of permeation and gating in an NMDA-channel pore mutant.

Authors:  R Schneggenburger; P Ascher
Journal:  Neuron       Date:  1997-01       Impact factor: 17.173

6.  Failure of the competitive N-methyl-D-aspartate antagonist Selfotel (CGS 19755) in the treatment of severe head injury: results of two phase III clinical trials. The Selfotel Investigators.

Authors:  G F Morris; R Bullock; S B Marshall; A Marmarou; A Maas; L F Marshall
Journal:  J Neurosurg       Date:  1999-11       Impact factor: 5.115

7.  Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial.

Authors:  G W Albers; L B Goldstein; D Hall; L M Lesko
Journal:  JAMA       Date:  2001-12-05       Impact factor: 56.272

8.  The incidence of unpleasant dreams after sub-anaesthetic ketamine.

Authors:  Mark Blagrove; Celia J A Morgan; H Valerie Curran; Leslie Bromley; Brigitte Brandner
Journal:  Psychopharmacology (Berl)       Date:  2008-10-24       Impact factor: 4.530

9.  Fractional calcium currents through recombinant GluR channels of the NMDA, AMPA and kainate receptor subtypes.

Authors:  N Burnashev; Z Zhou; E Neher; B Sakmann
Journal:  J Physiol       Date:  1995-06-01       Impact factor: 5.182

10.  Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists.

Authors:  D W Choi; J Y Koh; S Peters
Journal:  J Neurosci       Date:  1988-01       Impact factor: 6.167

View more
  1 in total

Review 1.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.